Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIIa study of 10-valent pneumococcal conjugate vaccine in healthy Swedish infants on a 2-4-11 month schedule
2005-003437-41Phase 3Completed
- Sponsor
- GSK
- Start
- Sep 2005
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of 10-valent pneumococcal conjugate vaccine in pneumococcal disease (2 arms), sponsored by GSK. Primary endpoint: Post-dose 2 pneumococcal antibody response. Started Sep 2005; status: completed.
02
Drugs
10-valent pneumococcal conjugate vaccine
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on 2005-003437-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003437-41.